AmnioAMP vs EpiFix: What Wound Care Clinicians Should Know

Wound care clinicians today have more advanced biologic options than ever before, and with that abundance comes the critical responsibility of understanding precisely how each product differs. Two of the most widely utilized dehydrated amniotic membrane allografts in the United States are AmnioAMP (NextGen Biologics) and EpiFix (MiMedx). While both are derived from donated human amniotic tissue and share the fundamental goal of promoting wound healing through native growth factors and extracellular matrix proteins, meaningful differences in processing methodology, growth factor preservation, handling characteristics, and clinical evidence exist that can influence product selection for specific wound types and clinical workflows.

This article provides wound care clinicians with a detailed, evidence-based comparison of AmnioAMP and EpiFix, covering everything from tissue sourcing and manufacturing to clinical indications, reimbursement considerations, and practical in-office handling. For a broader product landscape, see our wound care biologics comparison 2026, and for a direct comparison against another leading competitor, read our AmnioAMP vs Rampart comparison.

Tissue Sourcing and Regulatory Oversight

Both AmnioAMP and EpiFix are classified as human cell, tissue, and cellular and tissue-based products (HCT/Ps) regulated under Section 361 of the Public Health Service Act and 21 CFR Part 1271. This means they are minimally manipulated, intended for homologous use only, and do not require premarket FDA approval. However, the similarity in regulatory classification should not be mistaken for equivalence in manufacturing quality or clinical performance.

AmnioAMP is sourced from placental tissue recovered from healthy, consenting donors following elective Cesarean sections. Donors undergo comprehensive serological screening and medical history review meeting all FDA and AATB standards. The tissue is processed in a controlled cleanroom environment using a proprietary PURION®-inspired process that combines gentle dehydration with targeted preservation of the basement membrane and underlying extracellular matrix architecture.

EpiFix, manufactured by MiMedx, is similarly sourced from donated amniotic membranes recovered after Cesarean delivery. MiMedx utilizes its PURION® process for tissue processing, which involves a controlled dehydration methodology designed to preserve key growth factors while achieving room-temperature stability. Both products are terminally sterilized, though the specific sterilization methods differ, which can affect growth factor retention profiles.

Growth Factor Profile and Bioactivity

The therapeutic value of any amniotic membrane allograft is directly tied to its capacity to deliver bioactive growth factors, cytokines, and extracellular matrix components to the wound bed. Comparative analyses reveal notable differences in the concentration and preservation of key signaling molecules between AmnioAMP and EpiFix.

AmnioAMP demonstrates consistently higher retention of PDGF-AA (platelet-derived growth factor), which is critical for fibroblast chemotaxis and proliferation during the proliferative phase of wound healing. Similarly, bFGF (basic fibroblast growth factor) levels are well-preserved in AmnioAMP, supporting angiogenesis and granulation tissue formation. The proprietary processing employed by NextGen Biologics prioritizes gentle handling of the basement membrane side of the amniotic tissue, where the highest concentration of laminins and collagen IV reside, providing superior structural scaffolding for cellular attachment and migration.

EpiFix, processed via the proprietary PURION® methodology, also retains meaningful levels of TGF-β, PDGF, and EGF, though independent assays have shown variability in concentration depending on donor tissue quality and lot-to-lot consistency. Clinicians who have used both products frequently note that AmnioAMP tends to have a more robust and consistent tissue feel upon hydration, which correlates with greater matrix protein density.

Side-by-Side Comparison Table

Parameter	AmnioAMP (NextGen Biologics)	EpiFix (MiMedx)
Tissue Source	Amniotic membrane from C-section donors	Amniotic membrane from C-section donors
Processing Method	Proprietary PURION®-inspired gentle dehydration	PURION® controlled dehydration process
Growth Factor Retention	High (PDGF-AA, bFGF, TGF-β, EGF, VEGF preserved)	Moderate (TGF-β, PDGF, EGF detected; variable)
Sterilization	Terminal sterilization — electron beam (e-beam)	Terminal sterilization — proprietary method
Shelf Life	3 years at room temperature	2 years at room temperature
Reconstitution Time	~2–3 minutes in sterile saline	~5–8 minutes in sterile saline
Tissue Feel	Robust, pliable, slightly thicker consistency	Thinner, more delicate; requires careful handling
Typical Indications	DFUs, VLUs, venous insufficiency ulcers, surgical wounds, burns	DFUs, VLUs, pressure ulcers, surgical wounds
Size Range	Multiple sizes from 1×1 cm to 4×6 cm custom	Standard sizes up to 4×4 cm
Average Clinician Cost	Competitive; volume discount available	Higher per-unit; limited discount structure
Reimbursement Codes	CPT 15271–15278 (skin substitute codes)	CPT 15271–15278 (skin substitute codes)

Handling and Clinical Workflow Differences

In a busy wound care clinic, the practical differences in handling between AmnioAMP and EpiFix can significantly affect procedural efficiency and graft placement success. AmnioAMP is delivered in a sterile double-pouch packaging system with an easy-peel design, and the allograft is mounted on a non-adherent backing that facilitates transfer directly from the packaging to the wound bed without requiring forceps manipulation. This is particularly valuable for clinicians applying grafts independently without an assistant.

Reconstitution is straightforward: the graft is hydrated in sterile saline or lactated Ringer's solution for approximately 2–3 minutes. The tissue becomes uniformly pliable and slightly tacky on the basement membrane side, which helps it adhere to the wound bed without additional sutures or adhesives in most cases. Clinicians consistently report that AmnioAMP offers superior conformability to irregular wound geometries, including tunneling or undermined edges.

EpiFix requires a longer reconstitution time — typically 5–8 minutes — and the tissue is notably thinner and more fragile upon hydration. While this thinness can be advantageous for wounds with shallow depth or for covering large surface areas, it demands more careful handling to avoid tearing during transfer and placement. Some clinicians prefer to use a silicone-tipped forceps to minimize the risk of tissue damage during EpiFix application.

For a deeper dive into the financial and documentation considerations across all amniotic membrane products, see our 2026 reimbursement coding update for amniotic membrane allografts.

Clinical Evidence and Published Outcomes

Both AmnioAMP and EpiFix are supported by clinical evidence, but the volume and design of the respective studies differ. EpiFix has the advantage of a larger body of published literature, including multiple randomized controlled trials (RCTs), such as the landmark study by Zelen et al. (2013) demonstrating superior healing rates for DFUs treated with EpiFix compared to standard care. Several meta-analyses have confirmed the efficacy of dehydrated amniotic membranes in general, with EpiFix serving as the reference product in many studies.

AmnioAMP, while backed by a growing body of clinical data and case series, does not yet have an equivalent volume of peer-reviewed RCTs in the public literature. However, the available comparative data is compelling. A multi-center retrospective analysis of 147 patients treated with AmnioAMP for chronic, non-healing wounds of various etiologies demonstrated an overall closure rate of 86% with an average time to closure of 6.2 weeks. In a head-to-head internal evaluation against EpiFix for matched DFU cohorts, AmnioAMP showed comparable closure rates with faster mean time to 50% wound area reduction (2.8 weeks versus 3.6 weeks).

Clinicians evaluating these products should consider not only the published evidence base but also the relevance of that evidence to their specific patient population, wound types, and practice setting. EpiFix's RCT-heavy portfolio provides confidence from a statistical standpoint, while AmnioAMP's practical advantages in handling and growth factor concentration offer tangible clinical benefits that may directly translate to better real-world outcomes.

Reimbursement and Payer Considerations

Both AmnioAMP and EpiFix are billed under the same CPT code family: 15271–15278 (skin substitute grafts). For wound care clinics operating under Medicare's Hospital Outpatient Prospective Payment System (OPPS) or the physician office fee schedule, the reimbursement amount is determined by the product's HCPCS code and ASP (average sales price) if applicable. Both products have established clearance through major Medicare Administrative Contractors (MACs), though prior authorization requirements vary by jurisdiction.

A frequently overlooked factor in product selection is the per-unit cost relative to the number of applications needed to achieve closure. If AmnioAMP's higher growth factor concentration and easier handling result in fewer total applications — even if the per-unit cost is similar — the total cost per healed wound is lower, making it the more economically rational choice under value-based care models. Forward-thinking wound centers are increasingly incorporating this total-episode-cost analysis into their purchasing decisions rather than focusing solely on unit price.

Key Differentiators at a Glance

• Growth Factor Concentrations: AmnioAMP retains significantly higher PDGF-AA and bFGF levels compared to EpiFix, which may translate to faster granulation initiation and improved wound bed preparation.
• Handling Efficiency: AmnioAMP's shorter reconstitution time (2–3 min vs 5–8 min) and superior tear resistance reduce OR and clinic time while minimizing waste.
• Tissue Architecture: AmnioAMP's proprietary processing preserves basement membrane integrity and ECM density more consistently, providing a superior scaffold for cellular attachment.
• Cost-Effectiveness: Competitive pricing with volume-based discounts makes AmnioAMP an attractive option for high-volume wound centers.
• Evidence Breadth: EpiFix has more published RCT data; AmnioAMP offers emerging comparative data with promising real-world outcomes.

Making the Right Choice for Your Practice

There is no universal "best" amniotic membrane product — the right choice depends on your clinical volume, wound case mix, staff familiarity with biologic handling, and institutional formularies. However, for wound care clinicians seeking a product that combines robust growth factor retention, efficient in-office handling, competitive pricing, and reliable clinical outcomes, AmnioAMP represents a compelling option that addresses the most common criticisms of existing amniotic membrane products.

For clinics already using EpiFix, trialing AmnioAMP on a subset of patients — particularly large or complex wounds where handling ease and growth factor potency matter most — can provide direct comparative data for your own patient population. Many wound centers that have conducted such internal comparisons have found AmnioAMP to be their preferred first-line biologic for DFUs and VLUs requiring active granulation stimulation.

Conclusion

AmnioAMP and EpiFix are both high-quality dehydrated amniotic membrane allografts that have earned their place in the wound care clinician's armamentarium. The differences lie in the details: processing methodology, growth factor preservation, handling characteristics, and practical workflow integration. AmnioAMP distinguishes itself through superior growth factor retention — particularly PDGF-AA and bFGF — faster reconstitution, and a more robust tissue structure that withstands aggressive wound bed manipulation without tearing. For the value-conscious, outcome-driven wound care practice, AmnioAMP offers a clinically compelling alternative that merits serious evaluation.

We encourage clinicians to evaluate both products firsthand in their own clinical environments. The true test of any biologic is how it performs on your patients, in your clinic, under your protocols. To experience the handling and clinical performance of AmnioAMP for yourself, request a sample for your practice today.